**Title**

Clinical features and management of children with primary ciliary dyskinesia in England

**Authors**

Rubbo B1,2,3, Best S4, Hirst R5, Shoemark A4,6, Goggin P2, Carr SB4,7, Chetcuti P8, Hogg C4,7, Kenia P9, Lucas JS 1,2,3, Moya E10, Narayanan M5,11, O’Callaghan C11,12, Williamson M11, Walker WT1,2,3\*, on behalf of the English National Children’s PCD Management Service \*\*

\*Corresponding Author

\*\*Members of the English National Children’s PCD Management Service include: Amanda Harris, Amanda Friend, Victoria Keenan, Hannah Wilkins, Hasnaa Ismail-Koch, Andrea Burgess, Samantha Packham, Patricia Goggin, Gemma Marsh, Laura Baynton, Michael Leshen, Sarah Ollosson, Nicola Collins, Peter Rea, Ann-Louise McDermott, Amanda Parsons, Rajinder Kang, Nicola Lloyd, Alison Truscott, Lynne Schofield, l Knight

**Affiliations**

1. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
2. Primary Ciliary Dyskinesia Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
3. School of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton, UK
4. Paediatric Primary Ciliary Dyskinesia Service, Royal Brompton and Harefield Foundation Trust, London SW3 6NP, UK.
5. Centre for PCD Diagnosis and Research, Department of Infection, Immunity and Inflammation, Robert Kilpatrick Clinical Sciences Building, University of Leicester, LE2 7LX, Leicester, UK.
6. Clinical and Molecular Medicine, University of Dundee, Ninewells Hospital, Dundee, UK
7. National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6NP, London UK
8. Leeds Children’s Hospital, Leeds, UK
9. Birmingham Women’s and Children’s Hospital NHS Trust, Birmingham
10. Bradford Teaching Hospitals NHS Trust, Bradford, UK
11. Leicester National Primary Ciliary Dyskinesia diagnosis and management service, Department of Paediatrics, University Hospitals of Leicester NHS trust, Leicester.
12. UCL Great Ormond Street Institute of Child Health, GOSH NIHR BRC, London UK.

**Correspondence:**

Dr Woolf Walker, Primary Ciliary Dyskinesia Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK SO16 6YD

Word Count: 2684

**Keywords:** Primary ciliary dyskinesia, management, lung function, cystic fibrosis

**What is already known on this topic:**

* PCD is a rare autosomal recessive condition where abnormal ciliary function leads to impaired mucociliary clearance.
* Historically PCD has been considered a mild respiratory condition.
* There is little evidence to guide the management of children with PCD, with only one RCT published to date.

**What this study adds:**

* In England, FEV1 was lower in children with PCD compared to those with CF, particularly in younger age groups.
* Nutritional status should be considered in PCD management, as those with a lower BMI have significantly lower FEV1.
* Hearing impairment is common but seems to improve with age.

**ABSTRACT**

**Objective In England, the National Health Service** commissioned a National Management Service for children with primary ciliary dyskinesia (PCD). The aims of this study were to describe the health of children seen in this Service and compare lung function to children with cystic fibrosis (CF).

**Design Multi-centre service evaluation of the English National Management PCD Service.**

**Setting Four nationally commissioned PCD centres in England.**

**Patients** 333 children with PCD reviewed in the Service in 2015; lung function data were also compared to 2970 children with CF.

**Results** Median age at diagnosis for PCD was 2.6 years, significantly lower in children with situs inversus (1.0 vs 6.0 years, p<0.0001). Compared with national data from the CF Registry, mean (SD) %predicted FEV1 76.8% in PCD (n=240) and 85.0% in CF, and FEV1 was lower in children with PCD up to the age of 15 years. Approximately half of children had some hearing impairment, with 26% requiring hearing aids. Children with a lower BMI had lower FEV1 (p<0.001). One third of children had positive respiratory cultures at review, 54% of these grew *Haemophilus influenzae*.

**Conclusions** We provide evidence that children with PCD in England have worse lung function than those with CF. Nutritional status should be considered in PCD management, as those with a lower BMI have significantly lower FEV1. Hearing impairment is common but seems to improve with age. Well designed and powered randomised controlled trials on management of PCD are needed to inform best clinical practice.

Words: 247

**INTRODUCTION**

Primary ciliary dyskinesia (PCD) is a rare autosomal recessive condition where abnormal ciliary function leads to impaired mucociliary clearance. This loss of function to the mucociliary escalator leads to recurrent sinopulmonary infection and, ultimately, bronchiectasis. Historically it has been considered a mild respiratory condition; however, recent data suggests that lung function declines at a similar rate through childhood to children with cystic fibrosis (CF) (1–3). In addition, about 80% of patients suffer with persistent otitis media with effusion (OME) and associated conductive hearing loss (4,5). Half of the patients have situs inversus *totalis* (6) and up to 17% have congenital heart disease (CHD) (7,8). Many men are infertile due to immotile sperm and women can have reduced fertility (9,10). The estimated prevalence is 1 in 10,000 live births (11) (1) (1) (1) (1) (1) (1) (1) (1) but this can be significantly higher in certain populations (12,13).

In 2012, National Health Service (NHS) England commissioned a National Children’s PCD Management Service to complement the existing diagnostic service (14). Four PCD centres were commissioned to undertake annual review assessments, to a standardised service specification, by a specialist PCD multi-disciplinary team (MDT) on all children with PCD in England.

Here we describe the first full set of data collected from children at annual review, in 2015. We compare the lung function of children with PCD to those with CF in England and identify areas of future research that will help to improve patient care.

**METHODS**

Participants

All children with a diagnosis of PCD who had an annual review assessment between 1st January and 31st December 2015, in one of the four nationally commissioned PCD centres in England were included in this study. The diagnosis of PCD was confirmed by a specialist PCD diagnostic MDT, in line with ERS consensus guidelines (14,15). Annual reviews were carried out to a standardised service specification (14,16). To ensure that children received similar care across centres, national guidelines were developed, teams met regularly to discuss clinical cases and clinical outcome data were audited. The project was reviewed by the Research & Development office at University Hospital Southampton (UHS) and was deemed to be a service evaluation hence research ethics committee approval was not required (17).

Data collection

Data were extracted from electronic and paper medical records and from annual review reports, using a standardised data sheet, agreed a priori, with variables pre-defined in a coding manual. These included demographics, diagnostic information and a clinical review of the year, focused on respiratory, ENT and cardiac issues. Also collected were data on treatments, including airway clearance physiotherapy techniques and adjuncts, nebulised mucolytics, antibiotic use (oral and intravenous) both prophylactically and for exacerbations, inhalers and nasal treatments; anthropometry; and investigations, including spirometry, audiometry and collection of an airway microbiology sample. Centres were contacted to clarify any discordant or missing data.

**Investigations conducted at annual review assessment**

Spirometry data

Equipment was calibrated as per manufacturers’ instructions and all measurements were obtained according to the ERS/ATS guidelines (18). Global Lung Initiative (GLI) equations were used to estimate z scores for forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) from the data, ethnicity specific equations were used where available (19). GLI-based FEV1 z scores were obtained from the UK CF Registry for all English children in 2015 for direct comparisons with our PCD FEV1 data (20).

Audiology data

Hearing was defined as normal if <20 dB, mild loss if 20-40 dB, moderate loss if 40-70 dB, severe loss if 70 – 95 dB and profound loss if >95 dB.

Anthropometric data

Height and weight were performed and recorded in accordance with World Health Organisation (WHO) guidelines (21). Body mass index (BMI) z scores were calculated using the WHO Anthro Plus software version 3.2.2.

Statistical analyses

Data were cleaned, coded and analysed in Stata (version 14.0, Stata Corp, Texas, USA). Continuous variables were presented as mean with standard deviation (SD) or median with inter-quarter range (IQR).Groups were compared using independent t-tests, Mann-Whitney and Kruskal-Wallis tests. Post-hoc for pairwise comparisons were performed for FEV1 % predicted and age categories, with Tukey’s method to adjust for multiple comparisons. Categorical variables were reported as proportions and groups were compared using Chi-squared or Fisher’s exact test. Multiple regressions were used to model FEV1 z score, adjusting for possible covariates. Significant (p<0.05) variables were retained (backward selection) and results from the reduced regression model are reported. Normality of residuals was accessed using kernel density estimations and visual inspection of histograms. Results from the models were presented as number of observations, regression coefficients (r) with 95% confidence intervals and model’s goodness-of-fitness (adjusted R2). Spearman’s rank correlation coefficient was used to compare association between variables that were not normally distributed or between continuous and non-continuous variables.

**RESULTS**

Three hundred and thirty-three children with PCD underwent an annual review during the study period. Median age at review was 9.8 years, 52.6% of those reviewed were male and the majority were either white British (n=122, 36.6%) or Pakistani and British Pakistani (n=121, 36.3%) (Table 1, Supplementary Figure 1).

Diagnosis of PCD

Median age at diagnosis of PCD was 2.6 years (IQR 0.5 to 7.2 years) (Table 1). This was significantly lower in those with dextrocardia (n=172) compared to levocardia (n=151) (1.0 year of age (IQR 0.3 to 3.2, range 0 to 14.0) vs 6.0 years (IQR 2.0 to 9.0, range 0 to 16.2), p<0.001). 53.3% of children had dextrocardia with almost all having *situs inversus totalis*, only 12 patients (3.7%) had dextrocardia in isolation. CHD was reported in 13.1% of children Spirometry

Mean (SD) FEV1 z scores for children with PCD were -1.9 (1.4) and FVC z scores were -1.3 (1.5), mean predicted FEV1 (SD) was 76.8% (Table 1). FEV1 z score was significantly lower in older children, with a decrease of 0.6 z scores for every increase of 10 years in age (n=240, regression coefficient=-0.06, 95% CI -0.11 to -0.02, p=0.008, adjusted R2=2.9%; Figure 1a), adjusted for centre of origin, age at diagnosis, sex, cardiac situs and presence of cultured pathogens (Supplementary Table 1). Spirometry data from children with CF in 2015 was available as predicted FEV1 and hence this was used for comparison with our PCD patients (20). Mean predicted FEV1 was significantly lower in PCD children compared to CF children up to the age of 15 years (p=0.001), with no difference seen in the 16 to 18 years old category (p=0.7). The largest difference was in the 5 to 7-year olds, where the mean predicted FEV1 was 91.3% (SD=15.7%) in CF but was 78.3% (SD=18.6%) in PCD (Figure 1b) (20).

Mean (SD) BMI z scores in children with PCD were normal (z score=0 (1.4)) (Table 1). However, children with lower BMI also had lower FEV1 z scores (n=238, regression coefficient=0.35, 95%CI 0.22 to 0.47, p<0.001, adjusted R2=10.8%) (Figure 1c).

Microbiology

Microbiology data were available for 312 children, of which 67% did not culture a respiratory pathogen at annual review. *Haemophilus influenzae* was the most prevalent pathogen (17.9%, corresponding to 53.9% of those with a positive culture), followed by *Staphylococcus aureus* (5.1%) and *Streptococcus pneumoniae* (4.2%), with *Pseudomonas aeruginosa* cultured in 2.6% of children (Supplementary table 2). No children cultured non-tuberculous mycobacterium. There was no correlation between those culturing respiratory pathogens and FEV1 z scores and no statistically significant differences were observed in respiratory pathogens when stratified by age category (Figure 2).

Audiology

Normal hearing levels were observed in 44.3% of children with audiology results available (n=271; 81.4% of all children), 34% had mild hearing loss and 21.8% had more significant hearing loss. At the time of annual review 23.6% of children were wearing hearing aids. Moderate to profound hearing loss was seen in 26.4% of children younger than 6 years of age but in only 13.8% of those aged between 16 to 18 years (Figure 3). Once the children were under the care of the National Children’s PCD Management Service only two of the 333 children had ventilation tubes inserted.

Physiotherapy and mucolytic nebulisation

All children were trained to perform, and advised to undertake, regular age-appropriate airway clearance physiotherapy. The majority used either oscillating positive expiratory pressure (PEP) (49.2%) or PEP physiotherapy (32.1%) (Table 2). Approximately half of children (53.2%) were prescribed nebulised hypertonic saline as a mucolytic agent to aid airway clearance. Children using hypertonic saline had significantly lower FEV1 z scores (mean difference -0.4, 95% CI -0.76 to -0.04, p=0.028). Nebulised Dornase Alpha (Pulmozyme ®, Genentech, San Francisco, US) was used in only 4.9% of children.

Antibiotics

Thirty percent of children with PCD had at least one courses of intravenous (IV) antibiotics over the preceding 12 months. Approximately 10% of the children were prescribed regular IV antibiotics (Table 2). Those that received IV treatment had a lower FEV1 z score, adjusted for BMI z score and age (n=234, regression coefficient=-0.52, 95% CI -0.88 to -0.16, adjusted R2=17.5%). Children received a median of two courses of oral antibiotics over the preceding year (IQR 1 to 3). 59% were prescribed prophylactic antibiotics and of these, over half used Azithromycin (59.8%) (Table 2, Supplementary table 3). A significantly lower mean FEV1 z score was found in children taking prophylactic antibiotics, adjusted for use of antibiotics in the last year (IV or oral) and cultured pathogens (*n*=162, regression coefficient: -0.66, 95% CI -1.23 to -0.08, p=0.0008, adjusted R2=8.3%).

**DISCUSSION**

This study provides detailed characterisation of a large and well-defined group of children with PCD, diagnosed and managed under the unified, specialised National Children's PCD Management Service in England.

Historically, PCD has been considered a mild respiratory condition (22); however, we report a mean FEV1 of -1.9 z scores in children with the disease in England. Almost a third of children required admission for IV antibiotics over the preceding 12 months with over 10% receiving regular IV antibiotics. Further to this, whilst a recent large international PCD cohort found a similar reduction in lung function between children with PCD and CF, we showed that % predicted FEV1 was significantly lower in those with PCD compared to those with CF up to the age of 15 years, as was also observed in a smaller Danish cohort study (2, 3, 23). This suggests that in 2015, younger children seen by the National Children’s PCD Management Service had lower lung function than their European counterparts. However, lung function decline over time was steeper in CF patients and, by the age of 16 to 19 years, no statistically significant difference was seen between the two groups.

Our children had a median age at diagnosis of 2.6 years. This is considerably younger than previously reported in the literature (24), suggesting that the establishment of National Children’s PCD Diagnostic Service in 2006 and Management Service in 2012 might have raised awareness of this rare disease among paediatricians. However, newborn screening for CF was introduced in England in 2007 meaning that CF is generally diagnosed in infancy, allowing for early initiation of treatment. When comparing the spirometry data of our PCD children to those with CF, the largest differences in mean FEV1 were in younger children (Figure 1b). We therefore hypothesise that earlier diagnosis and initiation of treatment for PCD may improve the low values of FEV1 observed in younger children.

*Haemophilus influenzae*, as reported in previous studies, was the most frequent respiratory pathogen cultured in our patients (25, 26). Future studies clarifying the impact of chronic colonisation with this and other pathogens such as *Pseudomonas aeruginosa* in PCD patients are needed. Whilst these are cross-sectional data, we found no association between any cultured pathogen and FEV1. Well-powered longitudinal studies will be required to understand the impact of these pathogens on patients and, thereby, inform clinicians as to whether they should persist in attempting to eradicate them. Contrary to previous publications, the prevalence of respiratory pathogen did not vary between age groups, in particular there was no increase seen in the prevalence of *Pseudomonas aeruginosa* in older age groups (27).

A recently published large international cohort of children with PCD (28, 29) found that patients with lower BMI z scores have lower FEV1 z scores, which had not been observed previously (30). Our findings support this novel observation and are similar to well-described correlations in children with CF (31). However, the majority of CF patients have pancreatic insufficiency, which is not the case in PCD. This would therefore imply that having suppurative lung disease, independent of pancreatic issues, may impact negatively on nutritional status (or vice versa). These findings lead to the hypothesis that intervening on nutritional status may have a positive benefit on the respiratory health of children with PCD, as is the case in CF (32), and warrants further investigation.

Management of children with PCD is challenging due to the limited evidence base, with only one published randomised control trial (RCT) to date (33). Management is therefore based on expert opinion, consensus guidelines, and extrapolated from the larger evidence base available for patients with CF (15,34,35).

All children in the service were advised to undertake regular airway clearance physiotherapy (36). Over half the children used nebulised mucolytics agents, the vast majority using hypertonic saline. A RCT on use of hypertonic saline in PCD did not show improvement on quality of life in patients compared to controls (33); however, the study did not use a disease-specific quality of life questionnaire, was underpowered and the control group received normal saline nebulisation, which might in itself have been beneficial for the patients (37). We found that children on hypertonic saline had a significantly lower FEV1 than those not. This is likely due to clinicians reserving its use for children with a more severe clinical phenotype; however, further research is needed to exclude the possibility that hypertonic saline has a negative effect on lung function in children with PCD.

The use of prophylactic antibiotics in PCD remains controversial, as the potential decrease in the number of respiratory exacerbations must be balanced against the risk of increasing antimicrobial resistance. Despite this, in 2015, approximately 60% of our children were on prophylactic antibiotics, with over half of these using Azithromycin. These children were noted to have significantly lower FEV1 than those not on antibiotics. Again, clinicians likely reserved the use of prophylactic antibiotics for more severe, or frequently exacerbating children. Results from a multicentre study assessing the use of prophylactic azithromycin in PCD should soon be available and will help inform future management (38).

Almost a quarter of our children needed hearing aids for moderate to profound hearing loss. Hearing seems to improve with age but the high proportion of patients with some level of hearing loss stresses the importance of regular hearing assessments and ENT follow-up, particularly in early childhood, when hearing is fundamental to speech development. Only 2 out of 333 children in this study had ventilation tubes inserted under the care of the Service. The limited evidence for their use is both inconclusive and conflicting and a well-designed and powered study is needed to investigate this important area of management (39-42).

The strength of this work is in the large number of well-characterised children with PCD evaluated under a nationally standardised Management Service. However, the data are cross-sectional and therefore do not allow for conclusions to be drawn on, for example, the potential benefits of therapeutic interventions or the detrimental impact of culturing particular pathogens on clinical outcomes. Detailed longitudinal follow up of these children are therefore required and will help inform both management guidelines and therapies to be evaluated in future RCTs. Comparisons of lung function data between children with PCD and CF were limited to the data provided by the UK CF Registry (i.e. GLI-based spirometry measurements) and we were therefore unable to adjust CF data for potential confounders.

**CONCLUSIONS**

Our data suggests that, far from being a mild respiratory condition, children with PCD have worse lung function than those with CF, particularly at an earlier age. Those with a lower BMI have a significantly lower FEV1 therefore nutritional status should be considered in their management. Well designed and powered RCTs on the management of PCD are needed to inform best clinical practice.

**Acknowledgements**

The National PCD Service is commissioned and funded by NHS England. Research in Southampton is supported by NIHR Southampton Biomedical Research Centre and NIHR Wellcome Trust Clinical Research Facility. Research in Royal Brompton Hospital is supported by the NHLI, Imperial College London. Research in GOSH is supported by the NIHR GOSH BRC. Research in the University Hospitals of Leicester NHS Trust is supported by University of Leicester, Leicester. Research in Birmingham Women’s and Children’s Hospital NHS Trust is supported by the University of Birmingham and Wellcome Trust Clinical Research Facility. We would also like to thank all our shared care centres, our patients and the UK PCD Family Support Group.

**Competing Interest**

Dr. Lucas reports grants, personal fees and non-financial support from Aerocrine/ Circassia, grants and personal fees from Vertex, grants from Parion, outside the submitted work. Dr. Carr reports grants, personal fees and non-financial support from Vertex Pharmaceuticals, grants and other from Chiesi Pharmaceuticals, other from Pharmaxis Pharmaceuticals, personal fees from Actavis Pharmaceuticals, other from Profile Pharma, outside the submitted work.

**Contributions**

WW, JSL, SC, CH, PC, EM, MN, PK, CO’C and MW developed the concept and design of the study. WW and BR are responsible for the integrity of the study and data; BR led standardised clinical data collection, data management and statistical analyses; WW and BR drafted the manuscript; SB, BR, SC, PK, PC, EM, RH, AS, PG, MN and WW extracted of clinical data from patient record; WW, JSL, SC, CH, PC, EM, MN, PK, CO’C and MW led the diagnostic service and annual reviews at their respective centres; JSL provided guidance and critically reviewed the manuscript at an early draft. All co-authors critically reviewed and approved the final manuscript. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

**References**

1. Werner C, Lablans M, Ataian M, Raidt J, Wallmeier J, Große-Onnebrink J, et al. An international registry for primary ciliary dyskinesia. Eur Respir J. 2016 Mar;47(3):849–59.

2. Halbeisen FS, Goutaki M, Spycher BD, Amirav I, Behan L, Boon M, et al. Lung function in patients with Primary Ciliary Dyskinesia: an iPCD Cohort study. European Respiratory Journal. 2018;1801040.

3. Ring AM, Buchvald FF, Holgersen MG, Green K, Nielsen KG. Fitness and lung function in children with primary ciliary dyskinesia and cystic fibrosis. Respir Med. 2018;139:79–85.

4. Goutaki M, Meier AB, Halbeisen FS, Lucas JS, Dell SD, Maurer E, et al. Clinical manifestations in primary ciliary dyskinesia: systematic review and meta-analysis. Eur Respir J. 2016;48(4):1081–95.

5. Prulière-Escabasse V, Coste A, Chauvin P, Fauroux B, Tamalet A, Garabedian E-N, et al. Otologic features in children with primary ciliary dyskinesia. Arch Otolaryngol Head Neck Surg. 2010;136(11):1121–6.

6. Hirokawa N, Tanaka Y, Okada Y. Left-right determination: involvement of molecular motor KIF3, cilia, and nodal flow. Cold Spring Harb Perspect Biol. 2009;1(1):a000802.

7. Shapiro AJ, Davis SD, Ferkol T, Dell SD, Rosenfeld M, Olivier KN, et al. Laterality defects other than situs inversus totalis in primary ciliary dyskinesia: insights into situs ambiguus and heterotaxy. Chest. 2014;146(5):1176–86.

8. Best S, Shoemark A, Rubbo B, Patel M, Fassad MR, Dixon M, et al. Risk factors for situs defects and congenital heart disease in primary ciliary dyskinesia. Thorax. 2018;74(2):203-205

9. Vanaken GJ, Bassinet L, Boon M, Mani R, Honoré I, Papon J-F, et al. Infertility in an adult cohort with primary ciliary dyskinesia: phenotype-gene association. Eur Respir J. 2017;50(5).

10. Afzelius BA, Eliasson R. Male and female infertility problems in the immotile-cilia syndrome. Eur J Respir Dis Suppl. 1983;127:144–7.

11. Lucas JSA, Walker WT, Kuehni CE, Lazor R. Primary ciliary dyskinesia. In: Cordier J-F, editor. Orphan Lung Diseases. European Respiratory Society; 2011; DOI: 10.1183/1025448x.erm541012. O’Callaghan C, Chetcuti P, Moya E. High prevalence of primary ciliary dyskinesia in a British Asian population. Arch Dis Child. 2010;95(1):51–2.

13. Onoufriadis A, Paff T, Antony D, Shoemark A, Micha D, Kuyt B, et al. Splice-Site Mutations in the Axonemal Outer Dynein Arm Docking Complex Gene CCDC114 Cause Primary Ciliary Dyskinesia. Am J Hum Genet. 2013;92(1):88–98.

14. Lucas JS, Burgess A, Mitchison HM, Moya E, Williamson M, Hogg C, et al. Diagnosis and management of primary ciliary dyskinesia. Archives of Disease in Childhood. 2014;archdischild-2013-304831.

15. Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J. 2009;34(6):1264–76.

16. Harris A. Diagnosis and management of children with primary ciliary dyskinesia. Nurs Children Young People. 2017;29(7):38-47

17. Definying Research, Health Research Authority [Internet]. National Health Service; 2013 [cited 2018 May 24]. Available from: https://researchsupport.admin.ox.ac.uk/sites/default/files/researchsupport/documents/media/defining-research.pdf

18. Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, et al. Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. American Journal of Respiratory and Critical Care Medicine. 2017;196(11):1463–72.

19. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.

20. Carr S, Cosgriff R, Rajabzadeh-Heshejin V. Cystic Fribrosis: strength in numbers, UK Cystic Fibrosis Registry 2015 Annual Data Report [Internet]. 2016 Aug [cited 2018 May 24]. Available from: <https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources>

21. World Health Organization Department of Nutrition for Health and Development. WHO Child Growth Standards length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. 2006.

22. Dell SD. Primary ciliary dyskinesia: Myths and realities. Paediatr Child Health. 2008 Oct;13(8):668–70.

23. Marthin JK, Petersen N, Skovgaard LT, Nielsen KG. Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med. 2010 Jun; 181(11):1262-8.

24. Kuehni CE, Frischer T, Strippoli M-PF, Maurer E, Bush A, Nielsen KG, et al. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. Eur Respir J. 2010 Dec;36(6):1248–58.

25. Alanin MC, Nielsen KG, von Buchwald C, Skov M, Aanaes K, Høiby N, et al. A longitudinal study of lung bacterial pathogens in patients with primary ciliary dyskinesia. Clin Microbiol Infect. 2015 Dec;21(12):1093.e1-7.

26. Rogers GB, Carroll MP, Zain NMM, Bruce KD, Lock K, Walker W, et al. Complexity, temporal stability, and clinical correlates of airway bacterial community composition in primary ciliary dyskinesia. J Clin Microbiol. 2013 Dec;51(12):4029–35.

27. Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med. 2004 Feb 15;169(4):459–67.

28. Goutaki M, Halbeisen FS, Spycher BD, Maurer E, Belle F, Amirav I, et al. Growth and nutritional status, and their association with lung function: a study from the international Primary Ciliary Dyskinesia Cohort. Eur Respir J. 2017 Dec;50(6).

29. Marino LV, Harris A, Johnstone C, Friend A, Newell C, Miles EA, et al. Characterising the nutritional status of children with primary ciliary dyskinesia. Clin Nutr. 2018 Sep 7;

30. Maglione M, Bush A, Nielsen KG, Hogg C, Montella S, Marthin JK, et al. Multicenter analysis of body mass index, lung function, and sputum microbiology in primary ciliary dyskinesia. Pediatr Pulmonol. 2014;49(12):1243-50

31. Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol. 2006;20(3):531–46.

32. Konstan MW, Butler SM, Wohl MEB, Stoddard M, Matousek R, Wagener JS, et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr. 2003 Jun;142(6):624–30.

33. Paff T, Daniels JMA, Weersink EJ, Lutter R, Vonk Noordegraaf A, Haarman EG. A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia. Eur Respir J. 2017 Feb;49(2).

34. Lucas JS, Alanin MC, Collins S, Harris A, Johansen HK, Nielsen KG, et al. Clinical care of children with primary ciliary dyskinesia. Expert Review of Respiratory Medicine. 2017 Oct 3;11(10):779–90.

35. Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD, et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatric Pulmonology. 2016 Feb;51(2):115–32.

36. Schofield, L.M. Lloyd, N. Kang, R. Marsh, G. Keenan, V. and Wilkins, H.M. Physiotherapy English National Standards of care for children with Primary Ciliary Dyskinesia. J ACPRC. 2018 (50):71-82.

37. Kuehni CE, Goutaki M, Kobbernagel HE. Hypertonic saline in patients with primary ciliary dyskinesia: on the road to evidence-based treatment for a rare lung disease. Eur Respir J. 2017 Feb;49(2).

38. Kobbernagel HE, Buchvald FF, Haarman EG, Casaulta C, Collins SA, Hogg C, et al. Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia. BMC Pulm Med. 2016 Jul 22;16(1):104.

39. Andersen TN, Alanin MC, von Buchwald C, Nielsen LH. A longitudinal evaluation of hearing and ventilation tube insertion in patients with primary ciliary dyskinesia. Int J Pediatr Otorhinolaryngol. 2016 Oct;89:164–8.

40. Wolter NE, Dell SD, James AL, Campisi P. Middle ear ventilation in children with primary ciliary dyskinesia. Int J Pediatr Otorhinolaryngol. 2012 Nov;76(11):1565–8.

41. Majithia A, Fong J, Hariri M, Harcourt J. Hearing outcomes in children with primary ciliary dyskinesia--a longitudinal study. Int J Pediatr Otorhinolaryngol. 2005 Aug;69(8):1061–4.

42. Campbell RG, Birman CS, Morgan L. Management of otitis media with effusion in children with primary ciliary dyskinesia: a literature review. Int J Pediatr Otorhinolaryngol. 2009 Dec;73(12):1630–8.

**Tables**

**Table 1: Clinical and demographic data on children with PCD who underwent an annual review in 2015 across the four English National Children PCD Management Services**

|  |  |  |
| --- | --- | --- |
|  | **Mean (SD)** | ***n* with available data** |
| **Median age in years (IQR)** | 9.8 (5.5 to 13.8) | 333 |
| Male (%) | 175 (52.6%) | 333 |
| FEV1 z score | -1.9 (1.4) | 240 |
| FEV1 % predicted | 76.8% | 240 |
| FVC z score | -1.3 (1.5) | 240 |
| FVC % predicted | 85.4% | 240 |
| BMI z-score | 0 (1.4) | 307 |
| Weight z-score | -0.1 (1.3) | 159\* |
| Height z-score | -0.3 (1.1) | 310 |
| Age at diagnosis | 2.6 (0.5 to 7.2)\*\* | 321 |

SD: standard deviation; IQR: Inter-quarter range; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; BMI: body mass index; \*WHO Weight-for-age reference data are not available beyond age 10 hence *n* lower than for other anthropometric data (27) \*\* Median (IQR)

**Table 2: Management of Children with PCD in England in 2015**

|  |  |  |
| --- | --- | --- |
| **Physiotherapy modality** | ***n (%)*** | ***n with data available*** |
| Breathing techniques | 10 (3.3) | 299 |
| Exercise for airway clearance | 2 (0.7) | 299 |
| Manual techniques | 41 (13.7) | 299 |
| PEP physiotherapy (mask/Pari) | 96 (32.1) | 299 |
| Oscillating PEP | 147 (49.2) | 299 |
| Other | 3 (1.0) | 299 |
| **Antibiotics** |  |  |
| Number of IV antibiotic courses in past year | 95 (29.7) | 320 |
| Median (IQR) courses of oral antibiotics | 2 (1 to 3) | 254 |
| On regular IV treatment (every 3 to 6 months) | 34 (10.6) | 320 |
| On antibiotic prophylaxis | 189 (58.9) | 321 |
| **Other treatments** |  |  |
| Inhaled corticosteroids | 111 (34.2) | 325 |
| Bronchodilators | 156 (48.3) | 323 |
| Nasal rinsing | 123 (38.7) | 318 |

PEP: Positive expiratory pressure; IV: intravenous